Priyanka Mohan Lal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Priyanka Mohan Lal has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Anmol Mohan
Department of Internal Medicine, Carle Foundation Hospital, Urbana, IL, USA
10 shared publications - Usha Pharm. D Tejwaney
Valley health system, New Jersey, USA
8 shared publications - Vikash Kumar
Department of Internal Medicine, The Brooklyn Hospital Center, New York, USA
6 shared publications - Sarwan Kumar
Department of Internal Medicine, Wayne State University, Detroit, Michigan, USA
5 shared publications - Amna Mbbs Soulat
Ziauddin Medical University
3 shared publications - Hasiba Karimi
Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey
3 shared publications
Latest Publications
- Open Access
- 3 March 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (4) , 2566-2573
Association between atrial fibrillation and gastrointestinal bleeding: pathophysiology, risk stratification, and management – a narrative review
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, significantly increasing the risk of thromboembolic events, necessitating anticoagulation therapy. However, anticoagulation, particularly with novel oral anticoagulants, elevates the risk of gastrointestinal bleeding (GIB), creating a clinical dilemma in managing AF patients. This narrative review explores the pathophysiology linking AF and GIB, emphasizing the hypercoagulable state in AF and the mucosal damage caused by anticoagulants. Epidemiological data reveal that GIB incidence in AF patients ranges from 1.32% to 5.4% annually, with risk factors including older age, prior GIB, and concomitant antiplatelet use. Risk stratification tools such as CHA 2 DS 2 -VASc and HAS-BLED aid in balancing thromboembolic and bleeding risks, though their predictive performance remains modest. Comparative studies highlight that rivaroxaban carries a higher GIB risk, while apixaban offers a safer profile. Management strategies include proton pump inhibitors for prophylaxis, endoscopic interventions for acute bleeding, and individualized decisions on resuming anticoagulation post-GIB, typically within 7–30 days. Emerging research on the gut microbiome’s role in AF pathogenesis suggests potential novel therapeutic avenues. A multidisciplinary approach involving cardiologists, gastroenterologists, and hematologists is essential to optimize outcomes. Future directions include developing safer anticoagulants, refining risk prediction models, and exploring microbiome-targeted therapies.
- 3 March 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (4) , 2566-2573
Open AccessAssociation between atrial fibrillation and gastrointestinal bleeding: pathophysiology, risk stratification, and management – a narrative review
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, significantly increasing the risk of thromboembolic events, necessitating anticoagulation therapy. However, anticoagulation, particularly with novel oral anticoagulants, elevates the risk of gastrointestinal bleeding (GIB), creating a clinical dilemma in managing AF patients. This narrative review explores the pathophysiology linking AF and GIB, emphasizing the hypercoagulable state in AF and the mucosal damage caused by anticoagulants. Epidemiological data reveal that GIB incidence in AF patients ranges from 1.32% to 5.4% annually, with risk factors including older age, prior GIB, and concomitant antiplatelet use. Risk stratification tools such as CHA 2 DS 2 -VASc and HAS-BLED aid in balancing thromboembolic and bleeding risks, though their predictive performance remains modest. Comparative studies highlight that rivaroxaban carries a higher GIB risk, while apixaban offers a safer profile. Management strategies include proton pump inhibitors for prophylaxis, endoscopic interventions for acute bleeding, and individualized decisions on resuming anticoagulation post-GIB, typically within 7–30 days. Emerging research on the gut microbiome’s role in AF pathogenesis suggests potential novel therapeutic avenues. A multidisciplinary approach involving cardiologists, gastroenterologists, and hematologists is essential to optimize outcomes. Future directions include developing safer anticoagulants, refining risk prediction models, and exploring microbiome-targeted therapies.
- Open Access
- 7 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 8418-8425
Diabetes and liver cirrhosis: shared pathways and clinical implications – a narrative review
The global rise in type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) represents a critical and intertwined public health challenge. Both conditions share overlapping mechanisms, such as insulin resistance, lipid toxicity, chronic inflammation, and mitochondrial dysfunction, that drive disease progression and worsen outcomes. This review synthesizes emerging evidence on the bidirectional relationship between T2DM and MASLD, with a specific focus on underrecognized clinical intersections, including hepatogenous diabetes and the role of subclinical liver injury in diabetic patients. Unlike prior reviews, it emphasizes mechanistic links involving advanced glycation end products, cytokine dysregulation, and microvascular dysfunction, highlighting their implications for both hepatic and extrahepatic complications. We summarize epidemiological trends, outline gaps in current screening practices, and assess therapeutic strategies ranging from glycemic control and hepatoprotective antidiabetic agents to liver-directed interventions. Key takeaways for clinicians include the importance of early, integrated liver fibrosis assessment in diabetic care and the need for multidisciplinary approaches to reduce risks of cirrhosis, hepatocellular carcinoma, and mortality. By bridging pathophysiological insights with practical screening and treatment considerations, this review aims to guide more proactive and coordinated management of patients affected by T2DM and MASLD.
- 7 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 8418-8425
Open AccessDiabetes and liver cirrhosis: shared pathways and clinical implications – a narrative review
The global rise in type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) represents a critical and intertwined public health challenge. Both conditions share overlapping mechanisms, such as insulin resistance, lipid toxicity, chronic inflammation, and mitochondrial dysfunction, that drive disease progression and worsen outcomes. This review synthesizes emerging evidence on the bidirectional relationship between T2DM and MASLD, with a specific focus on underrecognized clinical intersections, including hepatogenous diabetes and the role of subclinical liver injury in diabetic patients. Unlike prior reviews, it emphasizes mechanistic links involving advanced glycation end products, cytokine dysregulation, and microvascular dysfunction, highlighting their implications for both hepatic and extrahepatic complications. We summarize epidemiological trends, outline gaps in current screening practices, and assess therapeutic strategies ranging from glycemic control and hepatoprotective antidiabetic agents to liver-directed interventions. Key takeaways for clinicians include the importance of early, integrated liver fibrosis assessment in diabetic care and the need for multidisciplinary approaches to reduce risks of cirrhosis, hepatocellular carcinoma, and mortality. By bridging pathophysiological insights with practical screening and treatment considerations, this review aims to guide more proactive and coordinated management of patients affected by T2DM and MASLD.
- Open Access
- 19 September 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (38) , e44237
Trends and disparities in acute coronary syndrome-related mortality in the United States: Implications for healthcare
Acute coronary syndrome (ACS) is a major cause of morbidity and mortality in the United States (US). However, the trends and disparities in ACS mortality are not well understood. This study aimed to analyze the ACS mortality in the US from 1999 to 2020 using the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research database. The age-adjusted mortality rates (AAMR) due to ACS were calculated for each year from 1999 to 2020, stratified by sex, race, urbanization, and state. The trends and disparities in AAMR were examined using descriptive statistics and graphical methods. The AAMR due to ACS decreased from 1999 to 2010 and for some variables till 2018, but then increased from 2018 to 2020. The AAMR due to ACS was higher in men than in women, non-Hispanic black adults than in non-Hispanic white adults and rural than in urban populations. The AAMR due to ACS varied widely among different states, with New York having the highest AAMR and Minnesota having the lowest AAMR. This study revealed the trends and disparities in ACS mortality in the US from 1999 to 2020. The study showed an increase in AAMR due to ACS in the recent years. The study also found significant disparities in AAMR due to ACS by sex, race, urbanization, and state. Further research is needed to explore the factors that contribute to the variation and inequality in ACS mortality.
- 19 September 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (38) , e44237
Open AccessTrends and disparities in acute coronary syndrome-related mortality in the United States: Implications for healthcare
Acute coronary syndrome (ACS) is a major cause of morbidity and mortality in the United States (US). However, the trends and disparities in ACS mortality are not well understood. This study aimed to analyze the ACS mortality in the US from 1999 to 2020 using the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research database. The age-adjusted mortality rates (AAMR) due to ACS were calculated for each year from 1999 to 2020, stratified by sex, race, urbanization, and state. The trends and disparities in AAMR were examined using descriptive statistics and graphical methods. The AAMR due to ACS decreased from 1999 to 2010 and for some variables till 2018, but then increased from 2018 to 2020. The AAMR due to ACS was higher in men than in women, non-Hispanic black adults than in non-Hispanic white adults and rural than in urban populations. The AAMR due to ACS varied widely among different states, with New York having the highest AAMR and Minnesota having the lowest AAMR. This study revealed the trends and disparities in ACS mortality in the US from 1999 to 2020. The study showed an increase in AAMR due to ACS in the recent years. The study also found significant disparities in AAMR due to ACS by sex, race, urbanization, and state. Further research is needed to explore the factors that contribute to the variation and inequality in ACS mortality.
- Open Access
- 30 July 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (8) , 5056-5061
Percutaneous, transpapillary, and transmural drainage in acute cholecystitis: a comparative analysis of techniques, stent selection, and clinical
Acute cholecystitis is a common inflammatory condition of the gallbladder, primarily caused by gallstone obstruction, leading to increased intraluminal pressure, ischemia, and infection. While laparoscopic cholecystectomy remains the standard treatment, gallbladder drainage techniques have emerged as effective alternatives for high-risk surgical patients. This review explores the indications, techniques, and comparative outcomes of various gallbladder drainage methods, including percutaneous transhepatic gallbladder drainage (PTGBD), endoscopic transpapillary gallbladder drainage (ETGBD), and endoscopic ultrasound-guided gallbladder drainage (EUS-GBD). Endoscopic ultrasound-guided transmural gallbladder drainage, particularly with lumen-apposing metal stents (LAMS), has shown high clinical success rates with fewer complications compared to traditional methods. Advances in stent technology and procedural techniques continue to improve patient outcomes. However, further research is needed to establish long-term efficacy and determine optimal patient selection criteria for different drainage methods. The review highlights the evolving landscape of gallbladder drainage and the need for standardized guidelines to optimize treatment strategies for high-risk patients.
- 30 July 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (8) , 5056-5061
Open AccessPercutaneous, transpapillary, and transmural drainage in acute cholecystitis: a comparative analysis of techniques, stent selection, and clinical
Acute cholecystitis is a common inflammatory condition of the gallbladder, primarily caused by gallstone obstruction, leading to increased intraluminal pressure, ischemia, and infection. While laparoscopic cholecystectomy remains the standard treatment, gallbladder drainage techniques have emerged as effective alternatives for high-risk surgical patients. This review explores the indications, techniques, and comparative outcomes of various gallbladder drainage methods, including percutaneous transhepatic gallbladder drainage (PTGBD), endoscopic transpapillary gallbladder drainage (ETGBD), and endoscopic ultrasound-guided gallbladder drainage (EUS-GBD). Endoscopic ultrasound-guided transmural gallbladder drainage, particularly with lumen-apposing metal stents (LAMS), has shown high clinical success rates with fewer complications compared to traditional methods. Advances in stent technology and procedural techniques continue to improve patient outcomes. However, further research is needed to establish long-term efficacy and determine optimal patient selection criteria for different drainage methods. The review highlights the evolving landscape of gallbladder drainage and the need for standardized guidelines to optimize treatment strategies for high-risk patients.
- Open Access
- 22 April 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (6) , 3610-3617
Navigating the crossroads: exploring the intersection of celiac disease and Budd–Chiari syndrome – insights, challenges, and management strategies
Celiac disease (CD) and Budd–Chiari syndrome (BCS) are distinct medical conditions affecting different organ systems. However, reports suggest a potential association between them. This review examines existing literature and summarizes the current knowledge regarding the connection between CD and BCS. The pathophysiology of both conditions involves immune dysregulation and prothrombotic tendencies, though through different mechanisms. Several case reports and small studies indicate an increased incidence of BCS in individuals with CD, but the underlying mechanisms remain unclear. Proposed hypotheses include chronic inflammation, hypercoagulability, and potential genetic factors. However, more robust studies are needed to establish a definitive association and elucidate the shared pathophysiological factors between the two conditions. Management of CD primarily involves strict adherence to a gluten-free diet, leading to symptom improvement and normalization of serological markers. BCS requires a stepwise approach involving anticoagulation, endovascular therapy, and, in severe cases, liver transplantation. Recognizing the potential implications of the coexistence of CD and BCS is crucial for developing appropriate management strategies. Further research is warranted to investigate the potential association between CD and BCS, including large-scale epidemiological studies, genetic analyses, and mechanistic investigations. Understanding the underlying mechanisms and identifying risk factors for BCS development in individuals with CD will contribute to enhanced diagnostic capabilities, refined management strategies, and improved patient outcomes.
- 22 April 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (6) , 3610-3617
Open AccessNavigating the crossroads: exploring the intersection of celiac disease and Budd–Chiari syndrome – insights, challenges, and management strategies
Celiac disease (CD) and Budd–Chiari syndrome (BCS) are distinct medical conditions affecting different organ systems. However, reports suggest a potential association between them. This review examines existing literature and summarizes the current knowledge regarding the connection between CD and BCS. The pathophysiology of both conditions involves immune dysregulation and prothrombotic tendencies, though through different mechanisms. Several case reports and small studies indicate an increased incidence of BCS in individuals with CD, but the underlying mechanisms remain unclear. Proposed hypotheses include chronic inflammation, hypercoagulability, and potential genetic factors. However, more robust studies are needed to establish a definitive association and elucidate the shared pathophysiological factors between the two conditions. Management of CD primarily involves strict adherence to a gluten-free diet, leading to symptom improvement and normalization of serological markers. BCS requires a stepwise approach involving anticoagulation, endovascular therapy, and, in severe cases, liver transplantation. Recognizing the potential implications of the coexistence of CD and BCS is crucial for developing appropriate management strategies. Further research is warranted to investigate the potential association between CD and BCS, including large-scale epidemiological studies, genetic analyses, and mechanistic investigations. Understanding the underlying mechanisms and identifying risk factors for BCS development in individuals with CD will contribute to enhanced diagnostic capabilities, refined management strategies, and improved patient outcomes.
- Open Access
- 10 June 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (12) , 7155-7163
Exploring the association between atrial fibrillation and celiac disease: a comprehensive review
Objective: This paper aims to provide a comprehensive overview of the pathophysiology of atrial fibrillation (AF) and celiac disease (CD) individually while also exploring the emerging evidence of a potential association between the two conditions. Methods: The pathophysiology of AF, the most prevalent arrhythmia globally, and CD, an autoimmune condition triggered by gluten consumption, is examined. Genetic, structural, electrophysiological, and inflammatory factors contributing to their development are explored. Results: AF involves irregular atrial activity leading to electrical and structural remodeling of the atrium. CD is characterized by an immune response to gluten, primarily associated with HLA-DQ2 and HLA-DQ8 genetic mutations, resulting in damage to intestinal tissue. Emerging research suggests a link between AF and CD, possibly mediated through inflammation, fibrosis, and electromechanical delays in the atrium. Conclusion: Understanding the association between AF and CD carries significant clinical implications. Recognition of this relationship can assist in identifying individuals at higher risk for AF and inform proactive management strategies. Additionally, it underscores the importance of comprehensive care for CD patients, considering potential cardiac implications. Further research is warranted to elucidate precise mechanisms and explore potential therapeutic interventions targeting common pathways, opening avenues for enhanced patient care and future investigations.
- 10 June 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (12) , 7155-7163
Open AccessExploring the association between atrial fibrillation and celiac disease: a comprehensive review
Objective: This paper aims to provide a comprehensive overview of the pathophysiology of atrial fibrillation (AF) and celiac disease (CD) individually while also exploring the emerging evidence of a potential association between the two conditions. Methods: The pathophysiology of AF, the most prevalent arrhythmia globally, and CD, an autoimmune condition triggered by gluten consumption, is examined. Genetic, structural, electrophysiological, and inflammatory factors contributing to their development are explored. Results: AF involves irregular atrial activity leading to electrical and structural remodeling of the atrium. CD is characterized by an immune response to gluten, primarily associated with HLA-DQ2 and HLA-DQ8 genetic mutations, resulting in damage to intestinal tissue. Emerging research suggests a link between AF and CD, possibly mediated through inflammation, fibrosis, and electromechanical delays in the atrium. Conclusion: Understanding the association between AF and CD carries significant clinical implications. Recognition of this relationship can assist in identifying individuals at higher risk for AF and inform proactive management strategies. Additionally, it underscores the importance of comprehensive care for CD patients, considering potential cardiac implications. Further research is warranted to elucidate precise mechanisms and explore potential therapeutic interventions targeting common pathways, opening avenues for enhanced patient care and future investigations.
- Open Access
- 22 April 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (6) , 3543-3550
MicroRNAs as promising biomarkers and potential therapeutic agents in breast cancer management: a comprehensive review
Breast cancer (BC), a complex and varied ailment, poses a significant global health burden. MicroRNAs (miRNAs) have emerged as vital regulators in BC progression, with potential implications for diagnosis and treatment. This review aims to synthesize current insights into miRNA dysregulation in BC. MiRNAs, small RNA molecules, govern gene expression post-transcriptionally and are implicated in BC initiation, metastasis, and therapy resistance. Differential expression of specific miRNAs in BC tissues versus normal breast tissue sheds light on underlying molecular mechanisms. MiRNAs also offer promise as diagnostic biomarkers due to their stable nature, accessibility in bodily fluids, and altered expression patterns in early-stage disease, augmenting conventional diagnostic methods. Beyond diagnosis, miRNAs also hold promise as therapeutic targets in BC. By modulating the expression of specific dysregulated miRNAs, it may be possible to restore normal cellular functions and overcome treatment resistance. However, several challenges need to be addressed before miRNA-based therapies can be translated into clinical practice, including the development of efficient delivery systems and rigorous evaluation through preclinical and clinical trials. MiRNAs represent a promising avenue in BC research, offering potential applications in diagnosis, prognosis, and therapeutic interventions. As our understanding of miRNA biology deepens and technology advances, further research and collaborative efforts are needed to fully exploit the diagnostic and therapeutic potential of miRNAs in BC management. Ultimately, the integration of miRNA-based approaches into clinical practice may lead to more personalized and effective strategies for combating this devastating disease.
- 22 April 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (6) , 3543-3550
Open AccessMicroRNAs as promising biomarkers and potential therapeutic agents in breast cancer management: a comprehensive review
Breast cancer (BC), a complex and varied ailment, poses a significant global health burden. MicroRNAs (miRNAs) have emerged as vital regulators in BC progression, with potential implications for diagnosis and treatment. This review aims to synthesize current insights into miRNA dysregulation in BC. MiRNAs, small RNA molecules, govern gene expression post-transcriptionally and are implicated in BC initiation, metastasis, and therapy resistance. Differential expression of specific miRNAs in BC tissues versus normal breast tissue sheds light on underlying molecular mechanisms. MiRNAs also offer promise as diagnostic biomarkers due to their stable nature, accessibility in bodily fluids, and altered expression patterns in early-stage disease, augmenting conventional diagnostic methods. Beyond diagnosis, miRNAs also hold promise as therapeutic targets in BC. By modulating the expression of specific dysregulated miRNAs, it may be possible to restore normal cellular functions and overcome treatment resistance. However, several challenges need to be addressed before miRNA-based therapies can be translated into clinical practice, including the development of efficient delivery systems and rigorous evaluation through preclinical and clinical trials. MiRNAs represent a promising avenue in BC research, offering potential applications in diagnosis, prognosis, and therapeutic interventions. As our understanding of miRNA biology deepens and technology advances, further research and collaborative efforts are needed to fully exploit the diagnostic and therapeutic potential of miRNAs in BC management. Ultimately, the integration of miRNA-based approaches into clinical practice may lead to more personalized and effective strategies for combating this devastating disease.
- Open Access
- 17 January 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (3) , 1531-1539
Impact of artificial intelligence on the diagnosis, treatment and prognosis of endometrial cancer
Endometrial cancer is one of the most prevalent tumours in females and holds an 83% survival rate within 5 years of diagnosis. Hypoestrogenism is a major risk factor for the development of endometrial carcinoma (EC) therefore two major types are derived, type 1 being oestrogen-dependent and type 2 being oestrogen independent. Surgery, chemotherapeutic drugs, and radiation therapy are only a few of the treatment options for EC. Treatment of gynaecologic malignancies greatly depends on diagnosis or prognostic prediction. Diagnostic imaging data and clinical course prediction are the two core pillars of artificial intelligence (AI) applications. One of the most popular imaging techniques for spotting preoperative endometrial cancer is MRI, although this technique can only produce qualitative data. When used to classify patients, AI improves the effectiveness of visual feature extraction. In general, AI has the potential to enhance the precision and effectiveness of endometrial cancer diagnosis and therapy. This review aims to highlight the current status of applications of AI in endometrial cancer and provide a comprehensive understanding of how recent advancements in AI have assisted clinicians in making better diagnosis and improving prognosis of endometrial cancer. Still, additional study is required to comprehend its strengths and limits fully.
- 17 January 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (3) , 1531-1539
Open AccessImpact of artificial intelligence on the diagnosis, treatment and prognosis of endometrial cancer
Endometrial cancer is one of the most prevalent tumours in females and holds an 83% survival rate within 5 years of diagnosis. Hypoestrogenism is a major risk factor for the development of endometrial carcinoma (EC) therefore two major types are derived, type 1 being oestrogen-dependent and type 2 being oestrogen independent. Surgery, chemotherapeutic drugs, and radiation therapy are only a few of the treatment options for EC. Treatment of gynaecologic malignancies greatly depends on diagnosis or prognostic prediction. Diagnostic imaging data and clinical course prediction are the two core pillars of artificial intelligence (AI) applications. One of the most popular imaging techniques for spotting preoperative endometrial cancer is MRI, although this technique can only produce qualitative data. When used to classify patients, AI improves the effectiveness of visual feature extraction. In general, AI has the potential to enhance the precision and effectiveness of endometrial cancer diagnosis and therapy. This review aims to highlight the current status of applications of AI in endometrial cancer and provide a comprehensive understanding of how recent advancements in AI have assisted clinicians in making better diagnosis and improving prognosis of endometrial cancer. Still, additional study is required to comprehend its strengths and limits fully.
- Top Cited PapersOpen Access
- 5 June 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (7) , 3506-3511
Vitamin D and polycystic ovary syndrome (PCOS): a review
A common health problem known as polycystic ovarian syndrome (PCOS), is characterized by irregular periods, an excess of androgen production, and polycystic ovaries. It is one of the most prevalent endocrine disorders in women of reproductive age, affecting 4–20% of women worldwide. Numerous studies have found a connection between the onset and symptoms of PCOS and Vitamin D insufficiency. Vitamin D insufficiency causes calcium dysregulation and follicular arrest in women with PCOS, which is connected to menstrual irregularities and fertility issues. Studies have connected PCOS metabolic alterations to VDR polymorphisms such as iApa-I, Taq-I, Cdx2, and Fok-I. Insulin resistance is directly related to Vitamin D, is one of the most distinctive characteristics of the PCOS phenotype. Thus, it is suggested that Vitamin D therapy may help PCOS patients with their insulin sensitivity. In addition to insulin resistance, cardiovascular issues are a second metabolic disturbance that PCOS patients with low Vitamin D levels experience. Dyslipidemia is not linked to an increased risk of cardiovascular disease in PCOS-affected women. Vitamin D dramatically improves glucose metabolism by increasing insulin production, insulin receptor expression and reducing pro-inflammatory cytokines. The effect of Vitamin D on the metabolic and reproductive dysfunctions associated with PCOS may be mediated by an overall impact on insulin resistance. Vitamin D supplementation improved menstrual periods, increased folliculogenesis, and decreased blood testosterone levels in PCOS patients, all of which had a significant impact on the ability to procreate. As a result, it might be a cutting-edge therapeutic strategy for treating PCOS concurrently.
- 5 June 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (7) , 3506-3511
Top Cited PapersOpen AccessVitamin D and polycystic ovary syndrome (PCOS): a review
A common health problem known as polycystic ovarian syndrome (PCOS), is characterized by irregular periods, an excess of androgen production, and polycystic ovaries. It is one of the most prevalent endocrine disorders in women of reproductive age, affecting 4–20% of women worldwide. Numerous studies have found a connection between the onset and symptoms of PCOS and Vitamin D insufficiency. Vitamin D insufficiency causes calcium dysregulation and follicular arrest in women with PCOS, which is connected to menstrual irregularities and fertility issues. Studies have connected PCOS metabolic alterations to VDR polymorphisms such as iApa-I, Taq-I, Cdx2, and Fok-I. Insulin resistance is directly related to Vitamin D, is one of the most distinctive characteristics of the PCOS phenotype. Thus, it is suggested that Vitamin D therapy may help PCOS patients with their insulin sensitivity. In addition to insulin resistance, cardiovascular issues are a second metabolic disturbance that PCOS patients with low Vitamin D levels experience. Dyslipidemia is not linked to an increased risk of cardiovascular disease in PCOS-affected women. Vitamin D dramatically improves glucose metabolism by increasing insulin production, insulin receptor expression and reducing pro-inflammatory cytokines. The effect of Vitamin D on the metabolic and reproductive dysfunctions associated with PCOS may be mediated by an overall impact on insulin resistance. Vitamin D supplementation improved menstrual periods, increased folliculogenesis, and decreased blood testosterone levels in PCOS patients, all of which had a significant impact on the ability to procreate. As a result, it might be a cutting-edge therapeutic strategy for treating PCOS concurrently.
- Open Access
- 22 August 2022
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 81, 104360
Increased burden of booster shots for COVID-19 amidst vaccine hesitancy in Pakistan
Pakistan is dealing with the fifth wave brought on by the new type, Omicron (or B.1.1.529) with 1,547,795 confirmed cases with 30,452 deaths of COVID-19, as reported by World Health Organization (WHO) from 2020 to 2022. Vaccination is the best tool to curb this pandemic and fight against the new variants as it reduces the likelihood that the disease will be severe. A two-dose regimen of the BNT162b2 vaccine provides 95% protection to people aged 16 years and above, against the novel coronavirus. However, like in other developing countries, the vaccination campaign in Pakistan is hampered due to vaccine hesitation. This might not be the last mutation the world shall face. As with any other virus, the corona-virus is also expected to mutate frequently in the future, making annual booster shots the only way to stay significantly immunized against this deadly virus. Communication and counseling are needed to build their trust while taking care of social inequalities in the population. The authorities must intensify their efforts and should address this very important issue.
- 22 August 2022
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 81, 104360
Open AccessIncreased burden of booster shots for COVID-19 amidst vaccine hesitancy in Pakistan
Pakistan is dealing with the fifth wave brought on by the new type, Omicron (or B.1.1.529) with 1,547,795 confirmed cases with 30,452 deaths of COVID-19, as reported by World Health Organization (WHO) from 2020 to 2022. Vaccination is the best tool to curb this pandemic and fight against the new variants as it reduces the likelihood that the disease will be severe. A two-dose regimen of the BNT162b2 vaccine provides 95% protection to people aged 16 years and above, against the novel coronavirus. However, like in other developing countries, the vaccination campaign in Pakistan is hampered due to vaccine hesitation. This might not be the last mutation the world shall face. As with any other virus, the corona-virus is also expected to mutate frequently in the future, making annual booster shots the only way to stay significantly immunized against this deadly virus. Communication and counseling are needed to build their trust while taking care of social inequalities in the population. The authorities must intensify their efforts and should address this very important issue.